Orris

Hypertension new guidelines

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

?

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

?

Reading File
Reading File
Finding Sources
Searching the Web

2025 hypertension guidelines AHA ACC new blood pressure targets

Searching PubMed

"hypertension"[MeSH Terms] AND "guideline"[pt]

Reading Web Page

https://www.ama-assn.org/public-health/prevention-wellness/n…

I have enough to give a solid, current summary. There are actually two major "new" hypertension guideline updates from 2024-2025: the US 2025 AHA/ACC High Blood Pressure Guideline and the 2024 ESC/ESH European Guidelines. Here's a synthesis of both.

2025 AHA/ACC High Blood Pressure Guideline (US, released August 2025)

This is the first major update since 2017, developed with the AMA and ~10 other societies.
BP categories (unchanged from 2017):
  • Normal: <120/80 mmHg
  • Elevated: 120-129 systolic, <80 diastolic
  • Stage 1: 130-139/80-89 mmHg
  • Stage 2: ≥140/≥90 mmHg (Diagnosis requires 2+ careful readings on 2+ separate occasions.)
What's new/emphasized:
  • Universal BP target reaffirmed at <130/80 mmHg for nearly all adults, regardless of age or diabetes status (exceptions: pregnancy, and individualized/less strict goals for frail or institutionalized patients via shared decision-making).
  • New risk tool - the PREVENT equation (Predicting Risk of CVD Events) replaces the old pooled cohort equations, incorporating cardiovascular, kidney, and metabolic health for more precise 10-year risk estimates.
  • Stage 1 hypertension with low risk (PREVENT 10-year risk <7.5%): start with lifestyle therapy alone, reassess with home + office BP at 3-6 months; if still ≥130/80, start pharmacotherapy.
  • Severe hypertension (>180/120 mmHg, non-pregnant): prompt evaluation and treatment with oral antihypertensives in the outpatient setting.
  • Cognitive protection: new Class 1A recommendation that achieving systolic BP <130 mmHg reduces risk of cognitive impairment and dementia - a first for a BP guideline.
  • First-line drug classes unchanged: thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers, and ACE inhibitors/ARBs, unless a compelling indication favors another agent. Guideline pushes single-pill combinations and once-daily dosing to improve adherence.
  • Renal denervation now addressed as an option for resistant hypertension in carefully selected patients via a multidisciplinary, shared decision-making process, based on newer efficacy trial data.
  • Strong emphasis on team-based, multidisciplinary care (physicians, pharmacists, APPs, nutritionists) and addressing structural/access barriers to control.
  • A companion AHA/ACC Scientific Statement (Dec 2025) further supports combination single-pill therapy to help patients reach goal faster.

2024 ESC/ESH European Guidelines (comparison)

  • Introduced a new intermediate category, "elevated BP" (120-139/70-89 mmHg), with treatment recommended down to <130/80 mmHg for most adults when tolerated.
  • More conservative in frail/elderly patients: ESH2023 and ESC2024 recommend individualized, less aggressive targets in frail patients (roughly 140-150 mmHg systolic), whereas AHA/ACC 2025 favors shared decision-making without a fixed numeric floor.
  • Both US and European guidelines converge on the <130/80 mmHg target for most non-frail adults, a shift driven by SPRINT and STEP trial data.

Other 2025 national updates

  • Hypertension Canada (2025) issued an updated primary care guideline for diagnosis and treatment in adults (PMID: 40419299).
  • JSH2025 (Japan) also adopted <130/80 mmHg for robust/mildly frail older adults, aligning with the US approach.
Sources:
Want me to go deeper into any one area - e.g., drug-class selection details, the PREVENT risk calculator, resistant hypertension/renal denervation criteria, or how this changes management for a specific patient population (diabetes, CKD, elderly)?
This is a shared conversation. Sign in to Orris to start your own chat.